Sex differences in response to angiotensin II receptor blocker-based therapy in elderly, high-risk, hypertensive Japanese patients: A subanalysis of the OSCAR study

Hypertension Research

Volumn 37, Issue 6, 2014, Pages 526-532

  Matsui, Kunihiko ^a   Kim Mitsuyama, Shokei ^b   Ogawa, Hisao ^b   Jinnouchi, Tomio ^c   Jinnouchi, Hideaki ^c   Arakawa, Kikuo ^d  

^a YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c Diabetes Care Center   (Japan)

^d FUKUOKA UNIVERSITY   (Japan)

Author keywords

calcium channel blocker; combination therapy; high dose ARB; Japanese; sex

Indexed keywords

AMLODIPINE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; AZELNIDIPINE; INSULIN; OLMESARTAN; ORAL ANTIDIABETIC AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; AZETIDINE 2 CARBOXYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DRUG INDUCED CANCER; FEMALE; FOLLOW UP; GERIATRIC DISORDER; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; AGE; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; ETHNOLOGY; JAPAN; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ASIAN CONTINENTAL ANCESTRY GROUP; AZETIDINECARBOXYLIC ACID; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; JAPAN; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 84902008361     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2014.23     Document Type: Article

References (17)

1. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm Jr RH, Hall WD, Jones WE, Kountz DS, Lea JP, Nasser S, Nesbitt SD, Saunders E, Scisney-Matlock M, Jamerson KA. Management of high blood pressure in blacks: an update of theinternational society on hypertension in blacks consensus statement. Hypertension2010; 56: 780-800.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ. The seventh report of the jointnational committee on prevention, detection, evaluation, and treatment of high bloodpressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
3. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydrochlorothiazide for hypertension inhigh-risk patients. New Engl J Med 2008; 359: 2417-2428.
4. Blauwet LA, Hayes SN, McManus D, Redberg RF, Walsh MN. Low rate ofsex-specific result reporting in cardiovascular trials. Mayo Clin Proc 2007; 82:166-170.
5. Ljungman C, Mortensen L, Kahan T, Manhem K. Treatment of mild to moderatehypertension by gender perspective: a systematic review. J Womens Health (Larchmt)2009; 18: 1049-1062.
6. Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K. Rationale, design andpatient baseline characteristics of olmesartan and calcium antagonists randomized(OSCAR) study: a study comparing the incidence of cardiovascular events betweenhigh-dose angiotensin II receptor blocker (ARB) monotherapy and combinationtherapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensivepatients (ClinicalTrials. Gov no. NCT00134160). Hypertens Res 2009; 32:575-580.
7. Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K.Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensivepatients. Am J Med 2012; 125: 981-990.
8. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, Ekbom T, Fagard R, Friedman L, Perry M, Prineas R, Schron E. Effect of antihypertensive drug treatment oncardiovascular outcomes in women and men. A meta-analysis of individual patient datafrom randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997;126: 761-767.
9. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ. A comparison of outcomes withangiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly.New Engl J Med 2003; 348: 583-592.
10. Safar ME, Smulyan H. Hypertension in women. Am J Hypertens 2004; 17: 82-87.
11. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. New Engl J Med 2007; 357:2189-2194.
12. Lagakos SW. The challenge of subgroup analyses-reporting without distorting. NewEngl J Med 2006; 354: 1667-1669.
13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Majoroutcomes in high-risk hypertensive patients randomized to angiotensin-convertingenzyme inhibitor or calcium channel blocker vs. diuretic: The antihypertensive andlipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288:2981-2997.
14. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, Laragh JH, Plat F, Battegay E, Calvo-Vargas C, Cieslinski A, Degaute JP, Holwerda NJ, Kobalava J, Pedersen OL, Rudyatmoko FP, Siamopoulos KC, Storset O. Outcomes in subgroups ofhypertensive patients treated with regimens based on valsartan and amlodipine: ananalysis of findings from the value trial. J Hypertens 2006; 24: 2163-2168.
15. Kim ES, Carrigan TP, Menon V. Enrollment of women in national heart, lung, and bloodinstitute-funded cardiovascular randomized controlled trials fails to meet currentfederal mandates for inclusion. J Am Coll Cardiol 2008; 52: 672-673.
16. Geller SE, Koch A, Pellettieri B, Carnes M. Inclusion, analysis, and reporting of sex andrace/ethnicity in clinical trials: have we made progress? J Womens Health 2011; 20:315-320.
17. Kohro T, Yamazaki T. Cardiovascular clinical trials in Japan and controversies regardingprospective randomized open-label blinded end-point design. Hypertens Res 2009;32: 109-114.